62% of GLP-1 requests were denied in 2024 — but up to 80% of well-documented appeals succeed. Answer a few questions about your specific denial and get a personalized appeal letter ready to send.
30-50% appeal success rate
45 days typical decision time
Free — no signup needed
Step 1 of 40%
What reason did your insurer give for the denial?
Check your denial letter — select the closest match
Not medically necessary
Insurer says criteria not met
Step therapy required
Must try other treatments first
Plan exclusion
"Not covered no matter what"
BMI/weight criteria not met
Doesn't meet numeric threshold
Missing documentation
Incomplete prior auth submission
Off-label use (weight loss)
Approved for diabetes only
Quantity/dose limit exceeded
Prescribed dose above plan limit
Not sure / general denial
Letter wasn't clear on the reason
What type of insurance plan do you have?
This determines which appeal rights and pathways apply to you
Employer plan (fully insured)
Subject to state insurance mandates
Employer plan (self-insured)
Large employer, ERISA-governed
ACA Marketplace plan
Purchased on healthcare.gov or state exchange
Medicare
Part D or Medicare Advantage
Medicaid
State-administered coverage
Not sure
I'll figure this out from my card/docs
A few details for your letter
This personalizes the appeal — all stays in your browser, nothing is saved
35%
Estimated baseline success rate for your situation — well-documented appeals with the right approach often do better
📄 Your personalized appeal letter
✓ Copied!
✅ Attach these documents with your letter
Your next steps
📞 If your physician gets a "peer-to-peer" review call
This is a phone call between your physician and the insurer's medical director. It can happen the same day and reverses denials surprisingly often. Share this with your doctor's office:
If your appeal doesn't succeed
Compounded semaglutide and tirzepatide through telehealth cost $99-199/month — often less than the copay on a denied-then-approved brand medication. You don't have to wait for the appeal to explore this option.
This tool generates a template letter based on common, evidence-based appeal language. It is not legal or medical advice and does not guarantee approval. Always have your prescribing physician review and customize the letter before submission, and consult your plan documents for your specific appeal deadlines and process.
Advertiser Disclosure: FuturWeightLoss.com receives compensation when you click some links on this page. The letter generator itself is completely free.
Why insurance denies GLP-1 medications — and what overturns denials
The majority of initial GLP-1 insurance denials are not permanent. Industry data suggests 40–60% of appealed GLP-1 denials are overturned — significantly higher than the appeal success rate for most other medication classes. Understanding why denials happen is the first step to reversing them.
The four most common denial reasons
Missing step therapy documentation — most plans require evidence that you've tried and failed metformin, orlistat, or another first-line agent. If your chart doesn't explicitly document this, even if it happened, the claim will be denied. Solution: have your physician document prior treatment attempts specifically.
BMI threshold not on the claim — GLP-1 coverage typically requires BMI ≥30, or ≥27 with a qualifying condition. If the BMI and qualifying condition aren't explicitly stated in the prior authorization request, insurers default to denial.
"Not medically necessary" boilerplate — the insurer's most common catch-all. Overturned most effectively with a physician letter citing specific clinical guidelines (AHA/ACC 2023 obesity guidelines) and the patient's documented comorbidities.
Formulary exclusion — some plans exclude GLP-1s entirely or only cover specific agents. Formulary exclusions are harder to overturn than medical necessity denials, but exceptions are possible when alternatives are contraindicated or have failed.
What makes an appeal succeed
The strongest appeals combine three elements: (1) a physician letter that explicitly cites clinical guidelines by name (ADA Standards of Care 2024, AHA/ACC obesity guidelines), (2) documented evidence of prior treatment attempts and their outcomes, and (3) specific description of the patient's comorbidities that create medical necessity. Appeals that treat it as a form to complete fail at much higher rates than appeals treated as a clinical argument.
Your rights under federal law
Under the ACA, you have the right to an internal appeal and, if that fails, an external review by an independent organization. External reviews overturn insurance decisions in 39–54% of cases across all medication types. For GLP-1 medications with clear clinical guidelines supporting their use, external review is a legitimate and underutilized pathway. Deadlines: internal appeal must be filed within the timeframe stated in your denial letter (typically 60–180 days); external review typically within 4 months of the internal appeal decision.
💊
If the appeal doesn't work — compounded semaglutide from $249/month
Insurance battles can take months. DirectMeds offers compounded semaglutide with no insurance required — physician consultation included, no membership fee. Many patients start here while their appeal is pending.
American Diabetes Association. Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1). diabetesjournals.org — Clinical guidelines frequently cited in successful GLP-1 prior authorization appeals.
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384:989–1002. doi:10.1056/NEJMoa2032183 — Clinical efficacy data for semaglutide; cite in medical necessity appeals.
HHS Office of Consumer Information and Insurance Oversight. External Review and Appeals Processes Under the ACA. hhs.gov — Your federal rights to appeal insurance denials and request external review.
Medical/legal disclaimer: Informational only. Not medical or legal advice. Consult a licensed physician and review your specific plan documents. Appeal deadlines and procedures vary by insurer and state.